We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

23 hedge funds and large institutions have $56.4M invested in Orchestra BioMed in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

19.04% less ownership

Funds ownership: 69.84% → 50.8% (-19%)

60% less capital invested

Capital invested by funds: $140M → $56.4M (-$83.5M)

63% less funds holding

Funds holding: 62 → 23 (-39)

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

91% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 43

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
23
Holders Change
-39
Holders Change %
-62.9%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
2
Reduced
9
Closed
43
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$9.91M
2
TCM
Tang Capital Management
California
+$3.89M
3
RL
RPO LLC
Connecticut
+$240K
4
Deutsche Bank
Deutsche Bank
Germany
+$149K
5
UBS Group
UBS Group
Switzerland
+$23.1K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$9.35M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.97M
3
SCM
Saba Capital Management
New York
-$7.34M
4
AC
Amitell Capital
Singapore
-$5.98M
5
SC
Sculptor Capital
New York
-$5.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Saba Capital Management
New York
– -$7.34M -737,488 Closed
AC
27
Amitell Capital
Singapore
– -$5.98M -600,139 Closed
SC
28
Sculptor Capital
New York
– -$5.41M -542,847 Closed
CC
29
Centiva Capital
New York
– -$4.82M -484,334 Closed
RCM
30
Radcliffe Capital Management
Pennsylvania
– -$4.06M -407,563 Closed
ACP
31
Acuta Capital Partners
California
– -$3.91M -392,500 Closed
WAM
32
Weiss Asset Management
Massachusetts
– -$3.05M -306,304 Closed
BFM
33
Boothbay Fund Management
New York
– -$2.98M -298,960 Closed
LSC
34
Logan Stone Capital
Illinois
– -$2.92M -292,967 Closed
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
– -$2.74M -275,298 Closed
Millennium Management
36
Millennium Management
New York
– -$2.53M -254,466 Closed
GL
37
Governors Lane
New York
– -$2.49M -250,000 Closed
KKRC
38
Kohlberg Kravis Roberts & Co
New York
– -$2.48M -248,924 Closed
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
– -$1.99K -200,000 Closed
ASM
40
ATW SPAC Management
New York
– -$1.91M -191,659 Closed
KPF
41
K2 Principal Fund
Ontario, Canada
– -$1.74M -175,000 Closed
KIM
42
Karpus Investment Management
New York
– -$1.6M -161,000 Closed
LP
43
LMR Partners
United Kingdom
– -$1.45M -145,108 Closed
PVI
44
Pura Vida Investments
New York
– -$1.04M -104,026 Closed
CM
45
Cohanzick Management
New York
– -$1.03M -103,824 Closed
SIM
46
Sandia Investment Management
Massachusetts
– -$1.01M -101,769 Closed
CIM
47
Cowen Investment Management
New York
– -$996K -100,000 Closed
RA
48
RiverPark Advisors
New York
– -$996K -100,000 Closed
Goldman Sachs
49
Goldman Sachs
New York
– -$937K -94,036 Closed
Marshall Wace
50
Marshall Wace
United Kingdom
– -$801K -80,467 Closed
1
2
3

OBIO Hedge Fund Activity: Q3 2022 in Review

23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2022, worth a combined $56.4M — down 60% from $140M a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of OBIO and 4 opened new positions — a net loss of 39 holders — while 9 trimmed existing stakes and 2 added.

The largest buyer was RTW Investments, opening a new position worth an estimated $9.91M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $9.35M sold.

  • 23 institutional investors held Orchestra BioMed (OBIO) as of Q3 2022, down from 62 in Q2 2022.
  • Funds reported $56.4M of Orchestra BioMed stock for Q3 2022, down 60% quarter-over-quarter.
  • 4 funds opened new Orchestra BioMed positions in Q3 2022 and 43 closed out, a net change of -39 holders.
  • The largest Orchestra BioMed buyer in Q3 2022 was RTW Investments, an estimated $9.91M added.
  • The largest Orchestra BioMed seller in Q3 2022 was D.E. Shaw & Co, an estimated $9.35M sold.

Based on aggregated 13F filings for Q3 2022.